Best Cardiac and Vascular Disorders Companies in Minnesota, United States
The 72 best Cardiac and Vascular Disorders companies in Minnesota, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: CVRx.
Ranked: Best Cardiac and Vascular Disorders companies in Minnesota
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CVRx Developer of implantable technology for hypertension and heart failure | $394M | 71 mo ago | 142 142 → 252 (+77%) | 2001 | — | Public | 284 patents Implantable baroreflex activation devices and minimally invasive electrode delivery systems | 1 partnership |
| 2 | Anteristech Provider of technologies for developing heart valve | $126M | 8 mo ago | 27 | 2006 | — | Public | — | — |
| 3 | Cardiovascular Systems Developer of devices for treating peripheral and coronary vascular disease | $121M | 159 mo ago | 780 | 1989 | — | Acquired | 4,124 patents Intravascular stents, catheters, and thrombectomy devices for cardiovascular interventions | — |
| 4 | Neochord Provider of minimally -invasive devise for valve repair | $108M | 15 mo ago | 7 | 2007 | David Chung President & CEO | Series E | 140 patents Minimally invasive cardiac valve repair devices and suture anchoring technologies. | — |
| 5 | 4C Medical Developer of medical devices for the treatment of mitral regurgitation | $88M | 15 mo ago | 28 | 2014 | Jeffrey Chambers Founder | Series D | 547 patents Patents concentrated in health & consumer products | — |
| 6 | Kips Bay Medical Medical device company innovating vascular technologies for cardiac surgeons | $63M | 135 mo ago | 13 | 2007 | — | Public | — | — |
| 7 | ev3 Endovascular Surgical products for treatment of Peripheral vascular & Neurovascular diseases | $59M | 288 mo ago | 1,307 | 2000 | — | Acquired | 80 patents Cardiovascular occlusion devices for septal and atrial defects | — |
| 8 | Atritech Latest women's fashion trends: flare skirts and tweed vests | $52M | 207 mo ago | 27 | 2000 | — | Acquired | 103 patents Left atrial appendage blood filtration and implant delivery devices | — |
| 9 | Cardionomic Neuromodulation therapy for heart failure | $47M | 56 mo ago | 15 | 2012 | — | Deadpooled | 115 patents Cardiac neuromodulation devices and signal‑processing for heart contractility control | — |
| 10 | Aria CV Device for pulmonary hypertension | $44M | 10 mo ago | 17 | 2010 | Dan Gladney Chief Executive Officer | Series B | 59 patents Implantable cardiovascular devices that modulate pulsatile pressure to treat pulmonary hypertension | — |
| 11 | Lutonix Global medical technology company advancing healthcare through innovative solutions and services | $35M | 186 mo ago | 9 | 2007 | Lixiao Wang Co-Founder & CTO | Acquired | 162 patents Patents concentrated in health & consumer products | — |
| 12 | Velocimed Interventional cardiology devices | $34M | 261 mo ago | — | 2001 | Dennis Wahr Founder & CEO | Acquired | 6 patents Medical closure devices and delivery tools for fluid containers | — |
| 13 | Tactile Medical Provider of lymphedema and venous ulcer treatment therapy and pumps | $23M | 164 mo ago | 592 592 → 1,106 (+87%) | 1995 | — | Public | — | 1 internship · 1 partnership |
| 14 | VDyne Developer of a medical device to treat tricuspid regurgitation | $21M | 65 mo ago | — | 1992 | Edward Malouf CEO | Series C | 178 patents Transcatheter heart valve delivery systems with side‑entry and cinching mechanisms | — |
| 15 | Vascudyne Developer of regenerative biomaterials for tissue repair and replacement | $18M | 13 mo ago | 6 | 2014 | Jeff Franco Co-Founder | Series A | 40 patents Engineered tissue implants for cardiovascular valves, grafts, and nerve repair | — |
| 16 | Hyloris Developer of drugs for rare and orphan disease conditions | $16M | 73 mo ago | 14 | 2014 | Stijn Rompay CEO | Public | — | 1 expansion |
| 17 | Cardio Flow Developer of orbital atherectomy platform for treating calcified and fibrotic plaque | $16M | 24 mo ago | 2 | 2014 | Michael Kallok President and CEO | Series A | 170 patents Coronary rotational atherectomy and intravascular lithotripsy devices for plaque removal | — |
| 18 | Vascular Solutions Products for vascular diagnostics and interventional procedures | $12M | 197 mo ago | 562 | 1997 | — | Acquired | 85 patents Minimally invasive vascular closure, occlusion, and guidewire technologies for endovascular procedures. | — |
| 19 | InterValve Aortic valvuloplasty balloon catheter | $11M | 137 mo ago | 15 | 2008 | — | Acquired | 35 patents Catheter-based heart valve repair and measurement devices for mitral and aortic interventions | — |
| 20 | Piraeus Medical Developer of solutions for stroke thrombectomy procedures | $11M | 2 mo ago | — | 2021 | Jared Hutar Chief Executive Officer | Series B | — | — |
| 21 | Pursuit Vascular Hemodialysis catheter end caps | $11M | 118 mo ago | 7 | 2009 | — | Acquired | 33 patents Antimicrobial coatings for medical fluid delivery devices and connectors. | — |
| 22 | AdvancedCPR Solutions Improving CPR outcomes through innovative patient positioning solutions and training | $10M | 16 mo ago | 10 | 2015 | Phil Faris Co-Founder & CEO | Series A | — | — |
| 23 | Hemosphere Global healthcare company innovating and delivering medical solutions for patient care | $9M | 194 mo ago | — | 1987 | Patrick Wethington ex-CEO | Acquired | 32 patents Implantable vascular access connectors and customizable conduits for hemodialysis | — |
| 24 | Imricor Developer of magnetic resonance imaging compatible electrophysiology tools for the treatment of cardiac… | $9M | 81 mo ago | 61 61 → 96 (+57%) | 2006 | Steve Wedan President and CEO | Public | — | 1 job opening · 1 partnership |
| 25 | CHF Solutions A device for patients suffering from fluid overload | $9M | 73 mo ago | 30 | 2001 | John Erb Ex-CEO | Public | 84 patents Extracorporeal blood filtration and circulatory support devices for neonatal/pediatric patients | — |
| 26 | Shape Medical Systems Innovative cardiopulmonary exercise testing solutions for streamlined diagnosis and therapy optimization | $8M | 45 mo ago | 6 | 2004 | Andrew Hofmeister CEO | Board Leadership | Series A | — | — |
| 27 | Vios Medical Remote patient monitoring system for healthcare providers | $6M | 134 mo ago | 35 | 2012 | — | Acquired | — | — |
| 28 | Cardia Products for transvenous closures of certain types of congenital heart defects. | $6M | 79 mo ago | 12 | 1998 | Joseph Marino CEO | Early Stage | 59 patents Percutaneous left atrial appendage occlusion devices and redeployable closure systems | — |
| 29 | Advanced Circulatory Therapy platform for blood flow regulation | $4M | 154 mo ago | 4,764 | 1997 | — | Acqui-Hired | 51 patents Respiratory support and CPR devices for intrathoracic pressure and cardiac arrest care | — |
| 30 | Peytant Solutions Developer of a regenerative medical device for the treatment of luminal diseases | $4M | 40 mo ago | — | 2008 | John Schorgl Co-Founder | Seed | 10 patents Amnion tissue‑coated vascular stents and delivery devices for regenerative cardiovascular therapy | — |
| 31 | Crossfire Medical Developer of medical devices for chronic venous insufficiency | $3M | 53 mo ago | 9 | 2016 | Scott Nelson Co-Founder | Seed | — | — |
| 32 | medicalCV Develops minimally invasive cardiac laser ablation systems | $2M | 236 mo ago | — | 2001 | Marc P Flores CEO & President | Deadpooled | 18 patents Real-time motion-controlled cardiac ablation laser systems for precise heart tissue treatment | — |
| 33 | CloSys Corporation Vascular closure device using natural clotting for closure | $2M | 120 mo ago | — | 2005 | Karol Nowakowski Founder and CTO | Series A | 14 patents Hemostatic wound closure devices employing clotting cascade activation | — |
| 34 | XCOIL Developer of medical device for the treatment of deep vein thrombosis | $2M | 107 mo ago | 4 | 2013 | Denis Harrington CEO | Seed | — | — |
| 35 | Geneticure Personalized hypertension treatment through DNA analysis for better medication selection | $1M | 110 mo ago | 9 | 2012 | — | Seed | 19 patents Genetic diagnostics and therapeutics for hypertension and coronavirus infections | — |
| 36 | Encore Medical Developer of transcatheter-based heart defect closure device | $1M | 49 mo ago | — | 2020 | Michael Corcoran CEO | Seed | — | — |
| 37 | Access Point Technologies Surgical robotics for minimally invasive endovascular intervention, improving patient care | $1M | 76 mo ago | 1 | 1999 | Steve Berhow Founder & CEO | Funding Raised | — | — |
| 38 | Zurich Medical Cardiovascular device innovator focused on cost-effectiveness and ease of use | $881K | 50 mo ago | 18 | 2013 | Paul Gam Chairman and CEO | Funding Raised | — | — |
| 39 | Hypertension Diagnostics Non-invasive device to measure elasticity of arteries | $834K | 171 mo ago | 3 | 1988 | Maury Taylor CEO | Acqui-Hired | — | — |
| 40 | BioMedix Diagnostic solutions for value-based care, population health, and vascular assessment | $682K | 163 mo ago | 15 | 1997 | — | Early Stage | 23 patents Patents concentrated in health & consumer products | — |
| 41 | Harbinger Medical Risk stratification system for cardiac disorders | $550K | 193 mo ago | — | 1993 | Harold H. Hoium Co-Founder | Deadpooled | — | — |
| 42 | Seigla Medical Developer of a catheter extension for coronary and peripheral vasculature procedures | $350K | 38 mo ago | 3 | 2017 | Chad Kugler President and CEO | Seed | — | 1 launch |
| 43 | AcQumen Medical Developer of hemodynamic monitor providing continuous cardiac output for pediatric patients | $341K | 7 mo ago | — | 2024 | Rodney Houfburg Co-Founder & CTO | Seed | — | 1 award |
| 44 | International Cardio Corporation Innovating non-invasive High-Frequency Focused Ultrasound (HIFU) medical device solutions | $300K | 173 mo ago | — | 2009 | Dennis Selka CEO | Seed | — | — |
| 45 | CoraVie Developer of FDA-approved patent-pending devices for the treatment of cardiac health | $295K | 46 mo ago | 2 | 2020 | — | Funding Raised | — | — |
| 46 | Nirva Medical Developer of a device to treat heart attack | $260K | 134 mo ago | — | 2010 | Pramote Hochareon Founder | Seed | — | — |
| 47 | Nonin Medical Noninvasive medical monitoring solutions | $148K | 132 mo ago | 176 176 → 255 (+45%) | 1986 | — | Funding Raised | 169 patents Nonin Medical patents cover non‑invasive wearable physiological monitoring, especially pulse oximetry and respiration detection. | 1 job opening · 1 launch |
| 48 | Kobara Medical Developer of an extravascular treatment for heart failure and cardiac arrhythmias | $120K | 97 mo ago | — | 2015 | Andreas Pfahnl CEO & President | Seed | — | — |
Top 12 Cardiac and Vascular Disorders companies in Minnesota
#1
Public · Eagan, Minnesota · founded 2006 · 27 employees$126.2Mraised▾
Provider of technologies for developing heart valve. The company has developed a 3D single-piece aortic valve called the DurAVR heart valve that uses its patented ADAPT technology. The other products developed are DurAVR leaflet repair (RP), DurAVR transcatheter heart valve (THV), DurAVR surgical heart valve (SHV).
- Oct 2025Post IPO$11.5M
- Apr 2024Post IPO$15.2M
- Mar 2022Post IPO$20M
- Oct 2021Post IPO$3.8M
#2
Series B · Maple Grove, Minnesota · founded 2021$11Mraised▾
Developer of solutions for stroke thrombectomy procedures. It offers Wrist-to-Brain thrombectomy system that combines an introducer sheath, guide catheter, and distal access catheter into one device to improve the care of patients suffering from Acute Ischemic Stroke.
- Mar 2026Series B$3.6M
- Oct 2025Series A$662.6K
- Sep 2025Series A$300K
- Feb 2025Series A$2M
#3
Series B · Saint Paul, Minnesota · founded 2010 · 17 employees$43.6Mraised▾
Aria CV is developing a medical device designed to improve the lives of patients living with the disease of pulmonary hypertension. Founded in 2010 by Drs. John Scandurra and Karl Vollmers, former Fellows at the University of Minnesota’s Medical Devices Center. Aria CV has an exclusive license to certain patents from the University of Minnesota. Aria CV’s device reduces the workload on the right side of the heart.
- Aug 2025Series B$1.4M
- Sep 2024Series B$2.2M
- Feb 2020Series B$31M
- Jan 2020Series A$666.6K
#4
Series E · Eden Prairie, Minnesota · founded 2007 · 7 employees$108.2Mraised▾
NeoChord is a medical device company that has developed the NeoChord DS1000 System for minimally-invasive mitral valve repair. Its flagship product is the NeoChord Artificial Chordae Delivery System which is CE marked and approved for sale in Europe.
- Feb 2025Series E$493.2K
- Aug 2024Series E$914.3K
- Apr 2021Series E$2.8M
- Feb 2021Series E$33.4M
#5
Series D · Brooklyn Park, Minnesota · founded 2014 · 28 employees$88.4Mraised▾
4C Medical is a developer of medical devices for the treatment of mitral regurgitation. The device is positioned supra-annular to the native mitral valve to stop the leak from entering the left atrium. It is structured like a net.
- Mar 2025Series D$175M
- Mar 2022Series C$35.4M
- Dec 2020Series B$10M
- Jun 2020Conventional Debt$100K
#6
Series A · Stillwater, Minnesota · founded 2014 · 6 employees$17.7Mraised▾
Developer of regenerative biomaterials for tissue repair and replacement. The company uses a proprietary Tissue technology platform to develop soft tissue implants and medical devices such as vascular graft for hemodialysis access.
- May 2025Grant (prize money)—
- Oct 2021Series A$17.7M
#7
Series A · Edina, Minnesota · founded 2015 · 10 employees$9.5Mraised▾
Improving CPR outcomes through innovative patient positioning solutions and training. This organization discovers, develops, and implements advanced CPR treatment strategies aimed at increasing neurologically favorable outcomes following cardiac arrest. They offer the EleGARD Patient Positioning System, a product designed to precisely, rapidly, and consistently position patients for effective CPR and airway management. The company provides comprehensive training materials and support resources to ensure proper utilization of their system. They are dedicated to advancing the science and research behind CPR techniques, sharing survivor stories, and engaging with the press to promote awareness. Their focus is on delivering solutions that enhance the effectiveness of CPR and improve patient outcomes.
- Feb 2025Grant (prize money)$394.1K
- Jan 2025Grant (prize money)$397K
- Nov 2022Series A$9.5M
- Sep 2022Grant (prize money)$394.8K
#8
Seed · Minneapolis, Minnesota · founded 2024$341.4Kraised▾
Developer of hemodynamic monitor providing continuous cardiac output for pediatric patients. The monitor utilizes ultrasound and impedance technology for noninvasive and accurate measurements. It empowers healthcare providers with clinically relevant measurements and data analytics.
- Oct 2025Conventional Debt—
- Oct 2025Seed$341.4K
#9
Series A · Saint Paul, Minnesota · founded 2014 · 2 employees$15.7Mraised▾
Developer of orbital atherectomy platform for treating calcified and fibrotic plaques. It offers FreedomFlow a modern atherectomy platform that provides physicians a way to treat complex PAD in a wide range of vessel diameters and has application in Atherectomy, Coronary Artery Disease, Peripheral Artery Disease, and Carotid Artery Disease.
- Jun 2024Series A$400K
- May 2023Series A$2M
- Aug 2021Series A$200K
- Apr 2021Series A$2.7M
#10
Public · Minneapolis, Minnesota · founded 2001 · 142 employees$394.1Mraised▾
CVRx is a developer of implantable technology for hypertension and heart failure. The product Barostim neo is implanted under the skin, similar to a pacemaker. It then sends signals to the body's cardiovascular regulators to improve cardiac and vascular function by restoring sympathovagal balance through activation of the afferent and efferent pathways of the autonomic nervous system. The product is CE marked and approved for sale in Europe for both indications.
- Jul 2020Series F$50M
- May 2019Series F$75.4M
- Aug 2016Conventional Debt$20M
- Sep 2014Venture Debt$15M
#11
Acquired · Saint Paul, Minnesota · founded 1989 · 780 employees$121.3Mraised▾
Developer of devices for treating peripheral and coronary vascular disease. The products include Orbital Atherectomy Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg and heart.
- Mar 2013Post IPO$13.5M
- May 2011Post IPO$40.1K
- Dec 2010Post IPO$3.5M
- Jan 2008Post IPO$11.2M
#12
Deadpooled · Forest Lake, Minnesota · founded 2012 · 15 employees$46.7Mraised▾
Cardionomic is developing a neuromodulation device to treat acute decompensated heart failure, in which fluid builds up in the lungs of patients. Hospitals admit 1 million people annually with the condition, which is currently treated with medications. The company has been issued 2 primary patents.
- Oct 2021Conventional Debt$5M
- Feb 2020Series C$15.8M
- May 2018Series B$9M
- Oct 2015Series B$21.8M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Cardiac and Vascular Disorders coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.